CA2092571A1 - Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes - Google Patents

Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes

Info

Publication number
CA2092571A1
CA2092571A1 CA002092571A CA2092571A CA2092571A1 CA 2092571 A1 CA2092571 A1 CA 2092571A1 CA 002092571 A CA002092571 A CA 002092571A CA 2092571 A CA2092571 A CA 2092571A CA 2092571 A1 CA2092571 A1 CA 2092571A1
Authority
CA
Canada
Prior art keywords
bcr
ribozyme
abl
cells
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002092571A
Other languages
English (en)
Inventor
David S. Snyder
John J. Rossi
Stephen J. Forman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
David S. Snyder
John J. Rossi
Stephen J. Forman
City Of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David S. Snyder, John J. Rossi, Stephen J. Forman, City Of Hope filed Critical David S. Snyder
Priority to CA002092571A priority Critical patent/CA2092571A1/fr
Priority to PCT/US1991/005443 priority patent/WO1993003141A1/fr
Priority to JP3514649A priority patent/JPH06501610A/ja
Priority to EP19910915940 priority patent/EP0551294A4/en
Priority claimed from PCT/US1991/005443 external-priority patent/WO1993003141A1/fr
Publication of CA2092571A1 publication Critical patent/CA2092571A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002092571A 1991-08-01 1991-08-01 Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes Abandoned CA2092571A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002092571A CA2092571A1 (fr) 1991-08-01 1991-08-01 Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes
PCT/US1991/005443 WO1993003141A1 (fr) 1991-08-01 1991-08-01 Inhibition par les ribozymes de l'expression du gene bcr-abl
JP3514649A JPH06501610A (ja) 1991-08-01 1991-08-01 Ｂｃｒ−ａｂｌ遺伝子発現のリボザイム阻害
EP19910915940 EP0551294A4 (en) 1991-08-01 1991-08-01 Ribozyme inhibition of bcr-abl gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002092571A CA2092571A1 (fr) 1991-08-01 1991-08-01 Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes
PCT/US1991/005443 WO1993003141A1 (fr) 1991-08-01 1991-08-01 Inhibition par les ribozymes de l'expression du gene bcr-abl

Publications (1)

Publication Number Publication Date
CA2092571A1 true CA2092571A1 (fr) 1993-02-02

Family

ID=4151351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092571A Abandoned CA2092571A1 (fr) 1991-08-01 1991-08-01 Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes

Country Status (3)

Country Link
EP (1) EP0551294A4 (fr)
JP (1) JPH06501610A (fr)
CA (1) CA2092571A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK500652015A3 (sk) 2015-10-15 2017-05-03 Ústav Polymérov Sav Spôsob úpravy funkčného stavu ľubovoľnej mRNA umožňujúci jej selektívne a špecifické rozpoznanie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004753A1 (fr) * 1989-10-02 1991-04-18 Cetus Corporation Conjugues d'oligonucleotides non codants et leurs emplois therapeutiques
WO1992000080A1 (fr) * 1990-06-26 1992-01-09 The Wistar Institute Of Anatomy & Biology Procede de traitement de leucemies

Also Published As

Publication number Publication date
EP0551294A4 (en) 1993-12-29
JPH06501610A (ja) 1994-02-24
EP0551294A1 (fr) 1993-07-21

Similar Documents

Publication Publication Date Title
EP0748383B1 (fr) Clivage cible de l'arn par ciblage de la ribonuclease p et sequences de clivage
Danko et al. Direct gene transfer into muscle
Leopold et al. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias
DE69734589T2 (de) Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase
JP4321877B2 (ja) トランス―スプライスにより生成される治療用分子
Ratajczak et al. Acute-and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
Halatsch et al. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor messenger RNA
KR0148782B1 (ko) 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터
US6183959B1 (en) Method for target site selection and discovery
US5686306A (en) Methods and reagents for lengthening telomeres
Hauswirth et al. Ribozyme uses in retinal gene therapy
EP0668782B1 (fr) Combinaison d'un agent anti-neoplasique et d'oligonucleotides antisens dans le traitement du cancer
Zhang et al. Silencing p21Waf1/Cip1/Sdi1 expression increases gene transduction efficiency in primitive human hematopoietic cells
US20050209182A1 (en) Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
WO1993003141A1 (fr) Inhibition par les ribozymes de l'expression du gene bcr-abl
Leopold et al. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia
CA2092571A1 (fr) Inhibition de l'expression du gene bcr-abl a l'aide de ribozymes
WO1995013383A1 (fr) Procedes et reactifs pour l'allongement des telomeres
AU2003295561A1 (en) Inhibitory oliogonucleotides targeted to bcl-2
US20230063739A1 (en) Cells having high adaptability under hypoxic conditions, and use thereof
RU2144080C1 (ru) Рибозим, способ инактивации рнк-мишени, способ получения рибозима
AU3986201A (en) Method and reagent for the inhibition of grid
US20030134806A1 (en) Method and reagent for the inhibition of grid
US20030092646A1 (en) Method and reagent for the inhibition of CD20

Legal Events

Date Code Title Description
FZDE Dead